INO SCHEDULE 13G: SEC filing

Tang Capital Management LLC and affiliated entities

Filed with the SEC on · accession 0001214659-26-014444

INO filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 16, 2026. Tang Capital Management LLC and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 17,978,200 shares (9.99%) of Inovio Pharmaceuticals common stock, including shares issuable upon exercise of pre-funded warrants. The stock moved -2.1% by the first close after the filing.

Summary of the filing

Tang Capital Management LLC and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 17,978,200 shares (9.99%) of Inovio Pharmaceuticals common stock, including shares issuable upon exercise of pre-funded warrants. The filing is a passive investment disclosure under Rule 13d-1(c).

Key details

Beneficial ownership of common stock by Tang Capital Management LLC$18.0M
Shares of common stock outstanding as of November 6, 2026$179.6M
Warrants beneficially owned by Tang Capital Management LLC$10.2M
IssuerInovio Pharmaceuticals, Inc.
Filer / beneficial ownerTang Capital Management LLC
Affiliate / beneficial ownerTang Capital Partners, LP
Affiliate / beneficial ownerTang Capital Partners International, LP
Affiliate / beneficial ownerTang Capital Partners III, Inc.
Affiliate / beneficial ownerTang Capital Partners IV, Inc.
Manager of tang capital management llc and ceo of tang capital partners iii and ivKevin Tang

How INO stock reacted

Close before

$1.43

Nov 13, 2026

First close after

-2.10%

$1.40

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for INO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for INO?

Click here

Frequently asked questions

What did INO file with the SEC on Nov 16, 2026?

INO filed a SCHEDULE 13G (SEC filing). Tang Capital Management LLC and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 17,978,200 shares (9.99%) of Inovio Pharmaceuticals common stock, including shares issuable upon exercise of pre-funded warrants. The filing is a passive investment disclosure under Rule 13d-1(c).

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did INO stock react to this filing?

INO closed at $1.43 before the filing and $1.40 on Nov 16, 2026 (-2.10%).

Other INO SEC filings

Get alerts when INO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days